Gene therapy is used for correcting defective genes that are responsible for disease development. Nucleic acid-based therapeutics are used to treat genetic disorders and diseases for which there exists no permanent cure, such as anaemia, sickle cell, cystic fibrosis, and thalassemia. The main technologies in nucleic acid-based gene therapy are anti-sense and anti-gene, short inhibitory sequences, gene transfer therapy, nucleoside analogues, ribozymes, aptamers, and others. The nucleoside analogues are a significant class of antiviral agents that are generally utilised in the therapy of human immunodeficiency virus (HIV) infection, hepatitis B virus (HBV), hepatitis C virus (HCV), and cytomegalovirus (CMV). The various applications include oncology, muscular dystrophy, muscular disorders, and rare diseases that are used by end-users such as hospitals and clinics and academic and research institutes. The nucleic acid-based gene therapy market research report is one of a series of new reports from The Business Research Company that provides nucleic acid-based gene therapy market statistics, including nucleic acid-based gene therapy industry global market size, regional shares, competitors with a nucleic acid-based gene therapy market share, detailed nucleic acid-based gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the nucleic acid-based gene therapy industry. This nucleic acid-based gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global nucleic acid based gene therapy market grew from $0.68 billion in 2022 to $0.75 billion in 2023 at a compound annual growth rate (CAGR) of 9.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The nucleic acid based gene therapy market is expected to grow from $1.06 billion in 2027 at a CAGR of 9.2%. Rising financial support by the government and the companies is projected to drive the demand for nucleic acid-based gene therapy. Nucleic acid therapeutics are analogs of naturally occurring acids or proteins responsible for genetic expression. The traditional therapies do not have any cure for the treatment of diseases such as cystic fibrosis, hemophilia, sickle cell anemia, thalassemia, and diabetes. Genetic profiling and molecular target identification form the backbone of these classes of drugs. Nucleic acid medication has greater potential for the treatment of these diseases, as they target the genetic basis of diseases and have a permanent cure. Rising financial support by the government and the companies dealing in the market for gene therapy is expected to contribute to increasing the demand for nucleic acid-based gene therapies. For instance, in August 2022, National Institute of Health (NIH) announced investment of $34 million annually for upcoming 5 years to develop HIV treatment research. The government support for gene therapies will contribute to the growth of the market. Stringent regulations imposed on gene therapies raise the price of gene therapies, which in turn hinders the demand for nucleic acid-based gene therapies. The excessive regulatory oversights create an expensive and elongated route for approval increasing the expenses. According to Foundation for Economic Education (FEE), unlike other drugs approved or regulated by the Food and Drug Administration (FDA), gene therapies are not only subject to the regulatory structure of the FDA, but also the Recombinant DNA Advisory Committee and Office of Biotechnology Activities. Also, as estimated by FEE, an approved gene therapy drug costs nearly $5.0 billion, which is five times higher than that of the average cost of FDA approval. The high cost of gene therapeutics drugs places them beyond the financial reach of the populace. This scenario is anticipated to restrain the market growth of the nucleic acid-based gene therapy market. The companies in the nucleic acid based gene therapy market are focusing on strategic partnerships and collaborations to help boost production. Major players are entering into partnership to expand their market and leverage each other’s resources. For example, in January 2022, Pfizer Inc., an American multinational pharmaceutical and biotechnology corporation, and Beam Therapeutics Inc., an American biotechnology company developing precision genetic medicines through base editing, announced an exclusive four-year research collaboration focused on in vivo base editing programs for three targets for rare genetic diseases of the liver, muscle and central nervous system. Similarly, in August 2022, Merck, an American multinational pharmaceutical company, and Orna Therapeutics, a US based biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, announced a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Major players in the nucleic acid-based gene therapy market are Celsion Corporation, Wave Life Sciences, Imugene, Caperna, Phylogica, Protagonist Therapeutics, Benitec Biopharma, EGEN, BioMedica, Transgene, and Copernicus Therapeutics. North America was the largest region in the nucleic acid-based gene therapy market in 2022. Western Europe was the second largest region in the global nucleic acid-based gene therapy market report.The regions covered in the global nucleic acid-based gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the nucleic acid-based gene therapy market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The nucleic acid based gene therapy market consists of sales of nucleic acid based gene therapy technologies such as anti-sense and anti-gene, short inhibitory sequences, gene transfer therapy, nucleoside analogs, ribozymes, aptamers, and other technologies. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part. The global nucleic acid based gene therapy market is segmented - 1) By Technology: Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologies 2) By Application: Oncology, Muscular Dystrophy/ Muscular Disorders, Rare Diseases 3) By End User: Hospitals And Clinics, Academic And Research Institutes

Oligonucleotide therapy refers to a collective term for cutting-edge molecular-targeting agents that use chemically produced oligonucleotides with single-stranded DNA (DNA) or RNA (RNA) backbones that have the potential for selectivity. Oligonucleotides are made to base-pair with a strand of DNA or RNA for the majority of applications. PCR primers are oligonucleotides' most popular application (polymerase chain reaction) The main types of oligonucleotide therapy are antisense oligonucleotides, aptamers, and others. Antisense oligonucleotides (AS ONs) are synthetic DNA oligomers that hybridise to a target RNA in a sequence-specific manner.They’ve been used to successfully limit gene expression, modify precursor messenger RNA splicing, and inactivate microRNAs. It is used in infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, kidney diseases, and others, and is implemented in hospitals, and research institutes. The oligonucleotide market research report is one of a series of new reports from The Business Research Company that provides oligonucleotide market statistics, including oligonucleotide industry global market size, regional shares, competitors with an oligonucleotide market share, detailed oligonucleotide market segments, market trends and opportunities, and any further data you may need to thrive in the oligonucleotide industry. This oligonucleotide market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global oligonucleotide therapy market grew from $1.1 billion in 2022 to $1.23 billion in 2023 at a compound annual growth rate (CAGR) of 12.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The oligonucleotide therapy market is expected to grow from $2.1 billion in 2027 at a CAGR of 14.2%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the oligonucleotide therapy market during the forecast period.For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. Therefore, the rise in cancer incidence rates globally is anticipated to boost demand for the oligonucleotide therapy market over the forthcoming years. The FDA's low number of drug approvals hampered the oligonucleotide therapy market during the forecast period. As of January 2020, the market only had 11 drugs approved for treatment, thus restraining the growth of the market. This can be attributed to the strict standards for manufacturing and high drug efficacy standards set by the regulatory bodies for approval of this therapy, thus increasing the time required for approval and limiting the growth of the market. The developers and providers of the oligonucleotide therapy market are investing in research and development to remodel the design of therapy to reduce its side effects on patients. The new and innovative oligonucleotides allow for precision medicine approaches and can be designed to selectively target any gene with minimal side effects. It also helps in targeting patient-specific sequences that are causative of rare diseases. In August 2020, the FDA granted accelerated approval to Viltepso (viltolarsen) injection, an antisense oligonucleotide for the treatment of Duchenne muscular dystrophy (DMD), which is a genetic disorder, with reduced side effects. In August 2020, Evotec SE, a Germany based pharmaceutical drug discovery and development company, announced a strategic partnership with Secarna Pharmaceuticals GmbH & Co. KG, a Germany-based antisense oligonucleotide company specialising in addressing significant unmet medical needs in immunology and immuno-oncology. Through this partnership, the multimodality platform of Evotec is further enhanced by this strategic cooperation with Secarna. In areas with a high unmet medical need, Evotec works to identify the best possible approaches to developing disease-modifying medications, whereas Secarna is a top supplier of tested ASO technology with a special platform to enable the identification and selection of ASOs in their early stages.. Major players in the oligonucleotide therapy market are Alnylam Pharmaceuticals Inc., Biogen Inc., Dynavax Technologies Corp., Ionis Pharmaceuticals Inc., Merck & Co. Inc., Miragen Therapeutics Inc., PCI Biotech Holdings ASA, Sarepta Therapeutics Inc., Jazz Pharmaceuticals and Bausch & Lomb. North America was the largest region in the oligonucleotide therapy market in 2022. The regions covered in the global oligonucleotide therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The oligonucleotide therapy market consists of sales of ASOs, siRNAs, miRNAs, and DNAzymes. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography, whether through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified), or as part of other products. The countries covered in the oligonucleotide therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The global oligonucleotide therapy market is segmented - 1) By Type: Antisense Oligonucleotide, Aptamer, Other Types 2) By Application: Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Other End-User 3) By End User: Hospitals, Research Institutes

Point-of-care (POC) molecular diagnostics refers to tests that detect the presence of specific nucleic acids in a clinical specimen, such as feces, saliva, urine, blood, and tissue. This molecular diagnostic is based on seeing targeted portions of microbial genetic material, DNA or RNA. It is utilized by the healthcare sector to detect emergency usage authorization to diagnose diseases. Point-of-care (POC) molecular diagnostic is used to detection of disease antigens or antibodies in human samples, such as mononucleosis, influenza, and group A streptococcus (GAS).  The main product and services of point-of-care molecular diagnostics are assays and kits, instruments and analyzers and software and services. Assays and kits refer to the equipment which is used in carrying out analyses such as studying disease pathways. Assays and kits were widely used for detecting rapid and accurate diagnosing and monitoring various diseases. Reverse transcription-polymerase chain reaction (RT-PCR), in situ-hybridization and sequencing are the technologies used in point-of-care molecular diagnostics that are used for diagnosis of diseases such as respiratory diseases, hospital-acquired infections (HAIs), cancer/oncology, hepatitis and hematology. Decentralized labs, hospitals, home care, and assisted living healthcare facilities use point of care molecular diagnostics. The point-of-care molecular diagnostics market research report is one of a series of new reports from The Business Research Company that provides point-of-care molecular diagnostics market statistics, including point-of-care molecular diagnostics industry global market size, regional shares, competitors with a point-of-care molecular diagnostics market share, detailed point-of-care molecular diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the point-of-care molecular diagnostics industry. This point-of-care molecular diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global point-of-care molecular diagnostics market size grew from $2.8 billion in 2022 to $3.14 billion in 2023 at a compound annual growth rate (CAGR) of 12.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The point-of-care molecular diagnostics market size is expected to grow to $4.98 billion in 2027 at a CAGR of 12.2%. The rapid growth in the increasing occurrence of infectious and respiratory diseases is expected to significantly contribute to the growth of the point-of-care molecular diagnostics market. Respiratory infections, such as viruses or bacteria, are caused by microorganisms that influence the respiratory system. These microbes can be transferred through coughing, sneezing, or direct touch. The severity of the respiratory medications includes a variety of inhalers, oral medications, intravenous treatments, and point-of-care molecular diagnostic to cure the patient. For instance, in May 2020, an annual Report on MCCD (Medical Certification of Cause of Death) 2020 shows that respiratory system diseases are the second most common cause of death, accounting for 10% of the total medically certified causes of death (88.7%). Furthermore, between 2019 and 2020, the number of deaths caused by respiratory disorders increased from 152,311 to 181,160. Therefore, the rapid occurrence of infectious and respiratory diseases and death will drive the point-of-care-molecular diagnostics market. Technological innovation is a key trend gaining popularity in the point-of-care molecular diagnostics market. Major companies operating in the point-of-care molecular diagnostics market are focused on providing technologically advanced solutions to strengthen their market position. These companies are implementing next-generation point-of-care molecular diagnostics technologies solutions and related services, such as enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), and mass spectrometry (MS), situ hybridizations, spectral karyotyping imaging, DNA microarrays, and others to implement on POC devices with features of accelerating analysis times and lowering costs. For instance, in March 2020, Abbott Laboratories, a US-based medical device company, launched the molecular point-of-care test available for detecting new COVID-19 (COVID-19). According to the company, the device shows positive results in five minutes and negative in 13 minutes. This test will run on the ID NOW™ platform with isothermal nucleic acid amplification technology that generates molecular results in minutes. In February 2021, Thermo Fisher Scientific, a US-based supplier of scientific instrumentation, reagents, consumables, and software services firm acquired Mesa Biotech for an undisclosed amount. With this acquisition, Thermo Fisher Scientific will expand into molecular diagnostics at the point-of-care by bringing much-needed diagnostics to market on a larger scale. Mesa Biotech is a US-based point-of-care molecular diagnostic company. Major players in the point-of-care molecular diagnostics market are Abbott Laboratories, F Hoffmann-La Roche Ltd., BioMérieux SA, Danaher Corporation, Quidel Corporation, Qiagen Gmbh, Biocartis NV, Nova Biomedical, Thermo Fisher Scientific, Dickinson and Company, Mesa Biotech Inc., OraSure Technologies Inc., Bio-Rad Laboratories Inc., Sysmex, Siemens Healthineers, Bayer HealthCare Pharmaceuticals LLC, Alere Inc., Lucira Health Inc., Cue Health, OpGen Inc., Binx Health Inc., Molbio Diagnostics Pct Ltd., Genomadix, Visby Medical, QuikPath PTE Ltd., QuantuMDx Group Ltd and Sekisui Medical Co Ltd. North America was the largest region in the point-of-care molecular diagnostics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the point-of-care molecular diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the point-of-care molecular diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The point-of-care (POC) molecular diagnostics market includes revenues earned by AAT, antigen, or antibody tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.  The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global point of care molecular diagnostics market is segmented - 1) By Product And Service: Assays And Kits, Instruments And Analyzers, Software And Services 2) By Technology: Reverse Transcription - Polymerase Chain Reaction (RT-PCR), In Situ Hybridization, Sequencing 3) By Application: Respiratory Diseases, Hospital Acquired Infections (HAIs), Cancer/Oncology, Hepatitis, Hematology 4) By End-User: Decentralized Labs, Hospitals, Home Care, Assisted Living Healthcare Facilities

Gene therapy refers to a method for treating or curing sickness that alters a person's DNA. Gene treatments can function in a variety of ways: putting a healthy copy of the gene in place of a disease-causing gene, and putting a defective gene that causes an illness inactive. The main types of gene therapy are antigens, cytokines, suicide genes, and others. The antigen is a poison or other foreign substance that triggers an immunological response in the body, including antibody formation. The different vectors include viral vectors, non-viral vectors, and others and are used in oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious diseases, and others. it is implemented in various sectors, such as hospitals, homecare, specialty clinics, and others. The gene therapy market research report is one of a series of new reports from The Business Research Company that provides gene therapy market statistics, including gene therapy industry global market size, regional shares, competitors with a gene therapy market share, detailed gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the gene therapy industry. This gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global gene therapy market grew from $7.37 billion in 2022 to $9.42 billion in 2023 at a compound annual growth rate (CAGR) of 27.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The gene therapy market is expected to grow from $24.03 billion in 2027 at a CAGR of 26.4%. Incidences of cancer and other target diseases have been increasing significantly, which is calling for effective treatments, driving the growth of the gene therapy market. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the gene therapy market during the forecast period. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. Therefore, the rise in the cancer incidence rate globally is anticipated to boost the demand for the gene therapy market over the forthcoming years. Gene therapy is one of the most effective treatments in oncology. In this treatment, new genes are introduced into a cancerous cell or the surrounding tissue to cause cell death or slow the growth of cancer. The high prices of gene therapy medicines are expected to limit the growth of the gene therapy market. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, the lack of cost-effective therapies for cancer and other diseases has influenced the health conditions of the population and led to a low average life expectancy. Luxturna, a one-time treatment for acquired retinal eye disease, costs $850,000 in the US and £613,410 in the UK, despite a markdown that is applied through Britain's National Health Service. Zolgensma, for spinal muscular atrophy, is valued at $2.1 million in the US, while Zynteglo, which focuses on a rare genetic blood disorder, costs $1.78 million, thus restraining the growth of the market. The use of machine learning and artificial intelligence is gradually gaining popularity in the gene therapy market. Artificial intelligence (AI) is the simulation of human intelligence in machines, which are programmed to display their natural intelligence. Machine learning is a part of AI. Machine learning and AI help companies in the gene therapy market conduct a detailed analysis of all relevant data, provide insights between tumour and immune cell interactions, and offer a more accurate evaluation of tissue samples, which is often disputed between different evaluators. For instance, since January 2020, GlaxoSmithKline, a pharmaceutical company, has been investing in AI to optimise gene therapy and develop off-the-shelf solutions for patients. It is also expected to reduce turnaround time and the cost of gene therapies. In December 2021, Novartis AG, a Switzerland-based pharmaceutical company specialising in the discovery, development, manufacturing, and commercialization of medicines, acquired Gyroscope Therapeutics Holdings plc for an amount of $800 million. Through this acquisition, GT005, an experimental, one-time gene therapy now in Phase 2 for the treatment of persons with geographic atrophy (GA), will be added to the Novartis portfolio, increasing gene therapy research capabilities and bringing ophthalmic innovation to treat and prevent blindness globally. Gyroscope Therapeutics Holdings plc is a UK-based clinical stage biopharmaceutical company pioneering in the research and development of gene therapies for the treatment of eye related diseases. Major players in the gene therapy market are Novartis AG, Bluebird Bio Inc., Spark Therapeutics Inc., Audentes Therapeutics, Voyager Therapeutics, Applied Genetic Technologies Corporation, UniQure N.V., Celgene Corporation, Cellectis S.A., and Sangamo Therapeutics. North America was the largest region in the gene therapy market in 2022. The regions covered in the global gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The gene therapy market includes revenues earned by entities by replacing a disease-causing gene with a healthy copy of the gene and inactivating a disease-causing gene that is not functioning properly. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global gene therapy market is segmented - 1) By Gene Type: Antigen, Cytokine, Suicide Gene, and Other Gene Types 2) By Vector: Viral Vector, Non-Viral Vector, Other Vectors 3) By Application: Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Other Applications 4) By End Users: Hospitals, Homecare, Specialty Clinics, Other End-Users

Molecular diagnostics devices are used to diagnose infectious diseases and perform screening by detecting specific sequences in DNA or RNA. It helps doctors prescribe more accurate therapeutic interventions in the early stages of a disease.  The main products of molecular diagnostics devices (or) equipment are instruments, reagents, and consumables. A reagent is a substance that is used to cause a chemical reaction. Reagents are used to indicate the presence of another substance. The technologies involved are DNA (deoxyribonucleic acid) sequencing, polymerase chain reaction, isothermal nucleic acid amplification technology, transcription-mediated amplification (TMA), in situ hybridization, microarrays, mass spectrometry, and others (southern blotting, northern blotting, and electrophoresis). The various applications are cancer, pharmacogenomics, genetic testing, infectious disease, prenatal, neurological disease, and cardiovascular disease, which are used by various end-users such as diagnostic laboratories, hospitals, and others (nursing homes, blood banks, point of care). The molecular diagnostics devices (or) equipment market research report is one of a series of new reports from The Business Research Company that provides molecular diagnostics devices (or) equipment market statistics, including molecular diagnostics devices (or) equipment industry global market size, regional shares, competitors with a molecular diagnostics devices (or) equipment market share, detailed molecular diagnostics devices (or) equipment market segments, market trends and opportunities, and any further data you may need to thrive in the molecular diagnostics devices (or) equipment industry. This molecular diagnostics devices (or) equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global molecular diagnostics devices and equipment market size will grow from $27.65 billion in 2022 to $30.82 billion in 2023 at a compound annual growth rate (CAGR) of 11.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The molecular diagnostics devices and equipment market size is expected to grow from $43.28 billion in 2027 at a CAGR of 8.9%. The growth in the molecular diagnostic devices and equipment market is attributed to factors such as the rapid rise in various bacterial and viral epidemics. The increase in the spread of diseases increases the demand for early and improved diagnostic methods. To improve the technology to enable the early diagnosis of such diseases, the Government and different organizations extend their financial support towards the major key players of the industry. For example, according to the reports from Centres for Disease Control and Prevention (CDC) US in October 2021, melioidosis was declared as a multistate epidemic. Thus, the rise of such chronic diseases serves as a prime driver for the players in the industry to develop more accurate and sophisticated diagnostic devices and equipment. Following the increase in demand for early diagnosis of B. pseudomallei, InBios, launched Active Meliodosis Detect™ point of care diagnostic test for the detection of B. pseudomallei. The regulatory process involving the approval of molecular diagnostic tests is often slow. The lack of clear definition coupled with constant changes in the regulations is a challenge for companies developing these kits. In developing nations such as India and China lack of a well-defined regulatory framework negatively impacts the market, irrespective of the presence of a large population. In the US market, because of the changes in the rules and regulations, the products already in the market may also be required to go through Food and Drug Administration (FDA)’s pre-marketing approval process. For example, CLIA (Clinical Laboratory Improvement Amendments Act) in the US certifies the validity of laboratory-based tests but it does not regulate the clinical validity of molecular diagnostic tests. This means that it does not control whether these results are clinically correct. This argument puts a restraint on the industry and opens an argument that FDA should play a greater role in overseeing laboratories. The major players in the molecular diagnostic industry are focusing on developing automated solutions for devices and equipment used for molecular diagnostic processes. Automation of the process will help to enhance the productivity and consistency of the whole diagnostic process. Computerization of the diagnostic process gives reliable and efficient test results that manual testing by various experts does not. The major players of the industry are using nanotechnology-based Oral Fluid Nano Sensor Test (OFNASET). The test uses a microfluidic-based nanosensor for the detection of oral cancer biomarkers in saliva. To keep up with the trend of automation and accuracy, Roche, created cobas connection modules (CCM) to improve scalability and sample-flow efficiency by allowing samples to automatically move between different systems and instruments. Thus, creating a fully automated workflow. The molecular diagnostic devices in the US are approved by Food and Drug Administration's (FDA) Center for Devices and Radiological Health (CDRH). These diagnostics devices are generally approved with an accompanying assay, to evaluate their safety and effectiveness or substantial equivalence regarding the assays they run and the assay's defined performance parameters. However, the same instruments do not require FDA approval or clearance when used for basic scientific research purposes. The European regulatory landscape has become more stringent and technically challenging for medical device companies. The introduction of four different risk classes of diagnostic devices i.e. classes A-D. Class A refers to the lowest risk tests and class D refers to the highest risk test such as HIV testing, blood grouping, and prenatal testing. Most of the genetic testing is classed into class C. The products bearing a CE mark, European approved tests, are safe to use, and are in full compliance. In March 2021, BioFire Diagnostics receive first marketing authorization from U.S. FDA for its BioFire Respiratory Panel 2.1. The product is a diagnostic product for simultaneous detection of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs obtained from patients. Major players in the molecular diagnostics devices (or) equipment market are Roche Ltd., Hologic, QIAGEN, Abbott, Danaher Corporation, Bio-Rad Laboratories, Siemens Healthcare, Becton Dickinson and Company, Cepheid Inc., and bioMerieux S.A. Asia-Pacific was the largest region in the global molecular diagnostics devices (or) equipment market in 2022. Western Europe was the second largest market in molecular diagnostics devices (or) equipment market. The regions covered in the global molecular diagnostics devices (or) equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the molecular diagnostics devices (or) equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, and Australia. The molecular diagnostics devices and equipment market consits of sales of thermocycler, single particle mass spectrometers, time-of-flight mass spectrometer (TOF) and others that are used to to detect pathogen and infectious diseases. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. This market is segmented into instruments, reagents, and consumables. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global molecular diagnostics devices and equipment market is segmented - 1) By Product: Instruments, Reagents, Consumables 2) By End User: Diagnostic laboratories, Hospitals, Others( nursing home, blood banks, point of care) 3) By Technology: DNA(Deoxyribonucleic acid) sequencing, Polymerase chain reaction, Isothermal Nucleic Acid Amplification Technology, Transcription Mediated Amplification (TMA), In situ hybridization, Microarrays, Mass spectrometry, Others (southern blotting, northern blotting, electrophoresis) 4) By Application: Cancer, Pharmacogenomics, Genetic testing, Infectious disease, Prenatal, Neurological disease, Cardiovascular disease

NGS-based RNA-sequencing is used to identify and measure the amount of ribonucleic acid (RNA) present in a biological sample at a certain moment, using next-generation sequencing (NGS). The massively parallel sequencing technology known as "next-generation sequencing" (NGS) provides extremely high throughput, scalability, and speed. This approach can ascertain the nucleotide sequence of whole genomes or specific DNA or RNA portions. The main products and services of NGS-based RNA sequencing are sample preparation products, sequencing platforms and consumables, sequencing services, and data analysis, storage, & management. Sample preparation products enable DNA or RNA to stick to the sequencing flowcell and enable identification of the sample. Sample preparation entails the procedures required to convert nucleic acid mixtures from biological samples into various types of libraries that are prepared for NGS technologies. Sequencing by synthesis, ion semiconductor sequencing, single-molecule real-time sequencing, and nanopore sequencing are the technologies. These sequencing techniques are used in expression profiling analysis, small RNA sequencing, de novo transcriptome assembly, and variant calling and transcriptome epigenetics. NGS-based RNA-sequencing is used by research & academia, hospitals & clinics, pharmaceutical & biotechnology companies, and other end users. The NGS-based RNA sequencing market research report is one of a series of new reports from The Business Research Company that provides NGS-based RNA sequencing market statistics, including NGS-based RNA sequencing industry global market size, regional shares, competitors with a NGS-based RNA sequencing market share, detailed NGS-based RNA sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the NGS-based RNA sequencing industry. This NGS-based RNA sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global NGS-based rna-sequencing market size grew from $2.22 billion in 2022 to $2.74 billion in 2023 at a compound annual growth rate (CAGR) of 23.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The NGS-based rna-sequencing market size is expected to grow to $6.3 billion in 2027 at a CAGR of 23.1%. The growth in precision medicine is driving the NGS-based RNA sequencing market. Precision medicine aids doctors in designing individualized treatment plans and making treatment decisions based on a genetic understanding of the patient's disease. There is a growth in precision medicines for treating severe diseases such as cancer. The NGS-based RNA sequencing helps identify the root cause of disease and prescribe specific precision medicine for treatment. For instance, in September 2021, the Swedish Government invested $21.15 million (SEK 220 million) in the Swedish national infrastructure Genomic Medicine Sweden (GMS), to make it easier to keep integrating precision medicine into Swedish healthcare, ensuring that every person there has to access to more accurate tests and individualized care. Such investments are taking place due to a rise in demand for precision medicines. As the demand for precision medicines increases, the demand for NGS-based RNA sequencing will also increase. Strategic Partnership is a key trend in the NGS-based RNA sequencing market. Companies are entering into a partnership with NGS-based RNA sequencing companies to expand in new markets and leverage each other's resources. For instance, in May 2022, The Biomedical Advanced Research and Development Authority (BARDA), a U.S. Department of Health and Human Services, partnered with multiple industry and academic partners. The partnership aims to improve the capacity to swiftly respond to public health emergencies and develop a novel diagnostic capability that covers all recognized and emerging respiratory RNA viruses in a single test. In March 2020, Illumina Inc., a US-based biotechnology company that develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function, partnered with IDbyDNA Inc. The partnership aims to give laboratories, and hospitals worldwide access to high-fidelity NGS analysis, interpretation, and reporting capabilities. The alliance hopes to enable the widespread distribution of NGS equipment, library prep, and other reagents. IDbyDNA Inc. is a US-based metagenomics technology company. In April 2021, Agilent Technologies, Inc., a US-based company that serves the life sciences, diagnostics, and applied chemical industries by offering analytical equipment, software, services, and consumables for the entire laboratory workflow, acquired Resolution Bioscience for $695 million. Through this acquisition, Agilent will expand its NGS-based cancer diagnostic capabilities and better meet the demands of the rapidly expanding precision medicine market. Agilent's ability to serve clinical diagnostics and biopharma customers is strengthened by the addition of Resolution Bioscience's liquid biopsy-based diagnostic technologies, which also expands the company's opportunities for growth in the diagnostics and genomics sectors. Resolution Bioscience is a US-based company involved in developing and commercializing next-generation sequencing (NGS)-based precision oncology solutions. Major players in the ngs-based rna-sequencing market are Illumina, Thermo Fischer Scientific, Oxford Nanopore, Agilent Technologies Inc., BGI, PerkinElmer Inc., QIAGEN, Eurofins Scientific, F. Hoffmann-La Roche Ltd., Takara Bio Inc., GENEWIZ Inc., Hamilton Company, Macrogen, and Bio-Rad Laboratories Inc. North America was the largest region in the NGS-based RNA sequencing market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in NGS-based RNA sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the NGS-based RNA sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The NGS-based RNA-sequencing market includes revenues earned by ribosomal RNA (rRNA), transfer RNA (tRNA), long ncRNA and many smaller ncRNAs such as microRNA. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.  The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global NGS based RNA sequencing market is segmented - 1) By Product And Service: Sample Preparation Products, Sequencing Platforms and Consumables, Sequencing Services, Data Analysis, Storage, and Management 2) By Technology: Sequencing by Synthesis, Ion Semiconductor Sequencing, Single-molecule Real-time Sequencing, Nanopore Sequencing 3) By Application: Expression Profiling Analysis, Small RNA Sequencing, De Novo Transcriptome Assembly, Variant Calling and Transcriptome Epigenetics 4) By End User: Research & Academia, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Other End Users

The pain management devices and therapies manage chronic and critical pain in patients suffering from various conditions, such as cancer and neurological disorder. These are mainly used for spinal cord stimulation, sacral nerve stimulators, and deep brain stimulation. The main types of pain management devices and therapies are electrical stimulators, ablation devices, neurostimulators, and analgesic pumps. The various electrical stimulation devices include transcutaneous electrical nerve stimulation (TENS) devices, neuromuscular electrical stimulation (NMES/EMS) devices, combination devices, electrotherapy devices, and TNS, ablation devices include radiofrequency ablation devices, cryoablation devices and neurostimulation devices including spinal cord stimulation (SCS) devices, deep brain stimulation devices, vagus nerve stimulation devices, and sacral nerve stimulation devices. The analgesic infusion pumps covered in this market are intrathecal infusion pumps, and external infusion pumps that are used for neuropathic pain, cancer pain, facial & migraine pain, musculoskeletal pain, and trauma applications. The pain management devices and therapies market research report is one of a series of new reports from The Business Research Company that provides pain management devices and therapies market statistics, including pain management devices and therapies industry global market size, regional shares, competitors with a pain management devices and therapies market share, detailed pain management devices and therapies market segments, market trends and opportunities, and any further data you may need to thrive in the pain management devices and therapies industry. This pain management devices and therapies market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global pain management devices and therapies market grew from $4.01 billion in 2022 to $4.38 billion in 2023 at a compound annual growth rate (CAGR) of 9.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The pain management devices and therapies market is expected to grow from $6.1 billion in 2027 at a CAGR of 8.6%. An increase in demand for pain management devices due rise in chronic diseases is driving the growth of the pain management devices and therapies market. Chronic diseases such as cancer, heart stroke often lead to unbearable pain in patients and thus creating a demand for pain management drugs and therapies. Chronic diseases persist over a long period and deteriorate the health of the patient. As reported in an article by the Brazilian Journal of Nephrology, around 60% of patients with chronic kidney disease reported pain of any kind of intensity, which required pain management drugs. Similarly, according to a report in the 'US National Library of Medicine, approximately 45% or 133 million of all Americans suffered from at least one chronic disease. It is also stated that more than two-thirds of all deaths are due to one of the chronic illnesses, which included coronary heart sickness, cancer, stroke, persistent obstructive pulmonary disease, and diabetes. This rise in chronic diseases is increasing the demand for pain management devices and therapies and driving the market. The availability of other alternatives to manage pain is restraining the growth of the pain management devices and therapies market. Alternatives treatment methods such as acupuncture, Marijuana treatment, dietary supplements, vitamins, etc. are being used instead of expensive pain relief devices and equipment. These alternative treatments may help with pain from bad backs, osteoarthritis, and headaches. For instance, the use of acupuncture works well for pain caused by many conditions, including fibromyalgia, osteoarthritis, back injuries, and sports injuries. Acupuncture is an ancient Chinese treatment that involves inserting thin pins through a person's skin at specific points on the body. Acupuncture comes with no prominent side effects and costs less compared to devices and equipment used to control pain. This rise in the use of alternative treatment methods is affecting the sales of pain management devices and therapies, and limiting the growth of the market. Companies in the pain management devices and therapies industry are focusing on the use of advanced technologies to cure chronic and acute pain without the use of any opioids (drugs). Special pain relief wearable devices are being developed by several companies that can be controlled manually or through a smartphone. These devices work by gathering neural pulses from the brain which triggers the release of the body's natural pain blocker. Thus, the devices electrically stimulate the nervous system and increase the body's resistance to pain. Companies such as NeuroMetrix, Sana, Oska wellness have introduced various types of wearable devices, ranging from a wearable mask, knee band, wrist band, etc. FDA has approved these devices as OTC (over-the-counter), which can be bought without a prescription. USFDA has defined the Pain Management Devices in section 882 under the medical devices market, under subchapter-H in Code of Federal Regulations (Title 21). Under these regulations, FDA requires the device manufacturers to register and list their devices with FDA and to follow general control requirements related to labeling, packaging, performance standards, and pre-market approval. To apply for premarket approval by FDA, the manufacturer is required to submit a premarket approval application that should include evidence providing reasonable assurance that the device is safe and effective. As per the FDA rule, the manufacturer can also submit a 510(k) notification demonstrating that the device is substantially equivalent to a device already on the market (a predicate device) that does not require a PMA. Major players in the pain management devices and therapies market are Abbott Laboratories, AstraZeneca, Pfizer, Boston Scientific Corporation, GlaxoSmithKline PLC., Teva Pharmaceutical Industries Ltd., Medtronic PLC., Novartis AG, Baxter International Inc., and Johnson & Johnson. North America was the largest region in the pain management devices and therapies market in 2022. Western Europe was the second largest region in the global pain management devices and therapies market report. The regions covered in the global pain management devices and therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the pain management devices and therapies market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The pain management devices and therapies market consists of sales of physical therapy, massage, acupuncture, osteopathic manipulative treatment (OMT) and chiropractic adjustments. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global pain management devices and therapies market is segmented - 1) By Type: Electrical Stimulators, Ablation Devices, Neurostimulators, Analgesic Pumps 2) By Application: Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, Trauma 3) By Electrical Stimulation Devices: Transcutaneous Electrical Nerve Stimulation (TENS) Devices, Neuromuscular Electrical Stimulation (NMES/EMS) Devices, Combination Devices, Electrotherapy Devices, TNS 4) By Ablation Devices: Radiofrequency Ablation Devices, Cryoablation Devices 5) By Analgesic Infusion Pumps: Intrathecal Infusion Pumps, External Infusion Pumps 6) By Neurostimulation Devices: Spinal Cord Stimulation (SCS) Devices, Deep Brain Stimulation Devices, Vagus Nerve Stimulation Devices, Sacral Nerve Stimulation Devices

Fetal and neonatal monitoring devices are used to assess the fetal heart rate and contractions of the uterus during pregnancy and childbirth. The main equipment of fetal and neonatal monitoring devices and equipment are fetal and neonatal. Neonatal monitoring devices and equipment are used for the monitoring of various body parameters of the newborn. Portable or non-portable fetal and neonatal monitoring devices and equipment Fetal care equipment types are ultrasound devices, fetal dopplers, fetal MRI systems, fetal monitors, and fetal pulse oximeters. Neonatal care equipment types are infant warmers, incubators, convertible warmers and incubators, phototherapy equipment, respiratory devices, neonatal monitoring devices, and diagnostic imaging devices. The various end-users are hospitals, diagnostic centres, pediatric clinics, and ambulatory surgical centres. The fetal and neonatal monitoring devices and equipment market research report is one of a series of new reports from The Business Research Company that provides fetal and neonatal monitoring devices and equipment market statistics, including fetal and neonatal monitoring devices and equipment industry global market size, regional shares, competitors with a fetal and neonatal monitoring devices and equipment market share, detailed fetal and neonatal monitoring devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the fetal and neonatal monitoring devices and equipment industry. This fetal and neonatal monitoring devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global fetal and neonatal monitoring devices market size will grow from $7.62 billion in 2022 to $8 billion in 2023 at a compound annual growth rate (CAGR) of 4.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The fetal and neonatal monitoring devices market size is expected to grow to $9.31 billion in 2027 at a CAGR of 3.9%. The increasing prevalence of preterm births and the low body weight of infants act as a factor driving the fetal and neonatal monitoring devices market growth. Preterm birth refers to the premature birth of a child before 37 weeks gestation period, which leads to poor health and growth, mental retardation, visual and hearing impairments, cerebral palsy, and others. According to World Health Organization (WHO), around 1 million babies die each year and preterm birth was found to be one of the top reasons for the deaths. According to the report by WHO, nearly 15 million babies are born preterm every year and this number is expected to have a continuous rise shortly. The increasing prevalence and need to reduce the infant mortality rates with improving healthcare conditions drives the fetal and neonatal monitoring devices market. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2021 the preterm birth rate in American women was 10.5%. The fetal and neonatal monitoring device market is restricted by stringent regulatory policies governing this market. The fetal and neonatal device manufacturers need to pass through several tests and requirements laid down by different regulatory bodies. Regulations like FDA's Center for Devices and Radiological Health (CDRH), NMPA regulations, EU directives lay down some stringent regulations for this equipment. The changes related to customer data protection such as the European Union's General Data Protection Regulation (GDPR), changes to equipment approval procedures, and other regulatory changes lead to increased healthcare costs. For instance, according to a report by Ernst and Young, Fortune 500 companies are spending $7.8 billion to comply with GDPR. The GDPR is an EU law on the data protection and privacy of individuals residing in the European Union and the European Economic Area (EEA). Furthermore, the FDA is requesting more clinical data to support claims resulting in increased processing times of 510(k)s by over 55% over the last decade, thus delaying the operating cycle of manufacturers in this market. Fetal and neonatal monitoring device manufacturers are increasingly innovating and integrating technologies such as wireless technology with patient monitoring devices to efficiently diagnose and monitor fetuses and newborns. Wireless sensor technology such as biosensor monitoring devices, wireless fetal heart rate monitoring devices is multi-sensor systems implanted or embedded into the skin, consisting of a sensor that transmits data for real-time monitoring of a patient’s medical condition. For instance, the National Institute of Neurological Disorders and Stroke developed SARA, a scanning device that can detect fetal brain activity with the help of flashes of light transmitted through the mother's abdomen. Philips developed a new cordless fetal monitoring device that helps in ensuring the safety of the mother as well as the child without any inconvenience and risk. These technological innovations eliminate poor reception of observation and help caregivers in monitoring more efficiently. Hong Kong’s Department of Health, a regulatory body for fetal and neonatal monitoring devices of Hong Kong, sent a medical device safety alert to Guangzhou Sunray Medical Apparatus Co., Ltd., a medical device manufacturer, concerning its maternal and fetal monitor. The safety alert was sent as the Guangzhou Sunray maternal and fetal monitor was delivering inaccurate ultrasound-derived fetal heart rate recordings due to software-related issues. These devices impacted patients’ health with delayed intervention resulting in severe injury or death to the fetus. To reduce incidences associated with these devices MRHA sent a medical device safety alert to correct the device. Similarly, in January 2021, Medtronic PLC., received Class II recall notice from the Food and Drug administration for its Neonatal valves due to problematic design. The faulty device resulted in shunt malfunction in certain cases. Major players in the fetal and neonatal monitoring devices and equipment market are GE Healthcare, Fisher & Paykel Healthcare Limited, Philips Healthcare, Atom Medical Corporation, Natus Medical Incorporated, Analogic Corporation, Phoenix Medical Systems (P) Ltd., Becton Dickinson, Masimo Corporation, and Drägerwerk AG & Co. KGAA Asia-Pacific was the largest region in the global fetal and neonatal monitoring devices and equipment market in 2022. North America was the second-largest region in the fetal and neonatal monitoring devices and equipment market. The regions covered in the global fetal and neonatal monitoring devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the fetal and neonatal monitoring devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, and Australia. The fetal and neonatal monitoring devices market consists of sales of instruments such as ultrasound devices, fetal dopplers, fetal MRI systems, fetal monitors, and fetal pulse oximeters. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global fetal and neonatal monitoring devices market is segmented - 1) By Equipment: Fetal, Neonatal 2) By End User: Hospitals, Diagnostic centers, Pediatric Clinics, Ambulatory Surgical Centers 3) By Portability: Portable, Non Portable 4) By Fetal Care Equipment Type: Ultrasound Devices, Fetal Dopplers, Fetal MRI Systems, Fetal Monitors, Fetal Pulse Oximeters 5) By Neonatal Care Equipment Type: Infant Warmers, Incubators, Convertible Warmers & Incubators, Phototherapy Equipment, Respiratory Devices, Neonatal Monitoring Devices, Diagnostic Imaging Devices